Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.
10.3350/kjhep.2011.17.2.120
- Author:
Ja Seon KIM
1
;
Young Min PARK
;
Nha Young KIM
;
Han Kyeol YUN
;
Ki Jong LEE
;
Bo Hyun KIM
;
Sang Jong PARK
;
Jae Woo YEON
;
Guhung JUNG
Author Information
1. Hepatology Center, Bundang Jesaeng General Hospital, Seongnam, Korea. ymp1@hotmail.com
- Publication Type:Original Article
- Keywords:
Hepatocellular carcinoma;
Arterioportal shunt;
Intratumoral injection chemotherapy;
Interferon-gamma
- MeSH:
Aged;
Angiography;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Carcinoma, Hepatocellular/*drug therapy/pathology/radiography;
Cisplatin/administration & dosage;
Epirubicin/administration & dosage;
Fluorouracil/administration & dosage;
Hepatic Artery;
Humans;
Infusions, Intra-Arterial;
Injections, Intramuscular;
Interferon-gamma, Recombinant/administration & dosage;
Liver Neoplasms/*drug therapy/pathology/radiography;
Male;
Tomography, X-Ray Computed;
Tumor Burden
- From:The Korean Journal of Hepatology
2011;17(2):120-129
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC). However, there is no effective treatment for advanced HCCs with arterioportal shunts (APS) or arteriovenous shunts (AVS). METHODS: We investigated a response and adverse events of a new combination protocol of repeated HAIC-EC and percutaneous intratumoral injection chemotherapy with a mixture of recombinant interferon-gamma (IFN-gamma) and 5-FU (PIC-IF) in patients with far-advanced HCCs with large APSs or AVSs. RESULTS: There was a complete response (CR) for the large vascular shunts in all three patients and for all tumor burdens in two patients. Significant side effects were flu-like symptoms (grade 2) and bone marrow suppression (grade 2 or 3) after each cycle, but these were well-tolerated. CONCLUSIONS: These results suggest that the combination of HAIC-EC and PIC-IF is a new and promising approach for advanced HCC accompanied by a large APS or AVS.